Article

Cyclosporine for SJS/TEN: A Case Series and Review of the Literature

Clear guidelines for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are lacking due to its infrequency and the absence of large controlled studies. Systemic corticosteroids and intravenous immunoglobulin (IVIG) have received considerable attention, though reports of the use of these agents have demonstrated mixed success rates in improving morbidity and mortality from SJS/TEN. We present a case series of 4 patients with SJS/TEN who rapidly responded to treatment with cyclosporin A (CsA). We discuss the proposed mechanism of action and the rationale for the use of cyclosporin based on the currently understood pathophysiologic mechanism of TEN.


 

Recommended Reading

Congress Fails to Fund Health Reform in 2011
MDedge Dermatology
Noncompliance With Topical Therapies Hampers Tx Effectiveness
MDedge Dermatology
Get Perspective on Serious Infections With Biologic Therapies
MDedge Dermatology
Shave Biopsies Accurately Identify Most Melanomas
MDedge Dermatology
Commentary: NIH Guidelines Offer Road Map for Managing Food Allergies
MDedge Dermatology
Commentary: The 3-Minute Goose Egg
MDedge Dermatology
Ischemia Predicts Poor Functional Outcomes in Diabetic Foot Ulcers
MDedge Dermatology
Commentary: Top 10 Infectious Disease Topics For 2011
MDedge Dermatology
CDC Updates STD Treatment Guidelines
MDedge Dermatology
Medicare Launches Physician Compare Web Site
MDedge Dermatology